CBT Presents Positive Preclinical Data for CBT-501 Colon Cancer Therapy
The anti-PD-1 antibody CBT-501 (genolimzumab) may offer hope to colon cancer patients, according to preclinical data recently presented by CBT Pharmaceuticals, a life sciences oncology company based in Santa Clara, California. During the ... Read more